Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
PGHL Stock Chart & Stats
₹5751.70
-₹54.70(-1.07%)
At close: 4:00 PM EST
₹5751.70
-₹54.70(-1.07%)
Day’s Range― - ―
52-Week Range₹4,725.05 - ₹6,700.00
Previous CloseN/A
Volume2.65K
Average Volume (3M)310.00
Market Cap
₹79.19B
Enterprise Value₹76.73B
Total Cash (Recent Filing)₹2.86B
Total Debt (Recent Filing)₹95.50M
Price to Earnings (P/E)30.5
Beta0.57
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)15.96
Price to Sales (P/S)7.03
P/FCF Ratio51.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹6,800.00Price Target Upside18.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)219
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and very high ROE give the company durable financial flexibility. Minimal debt limits interest risk and bankruptcy exposure, while high ROE signals efficient capital use, supporting reinvestment, M&A optionality and resilience through industry cycles over months to years.
Strong Cash GenerationA near‑par FCF to net income ratio demonstrates the business reliably converts earnings into cash, enabling sustained reinvestment, working capital funding and shareholder returns without reliance on external financing, supporting steady operations and strategic initiatives long term.
Consistent Profitability And Revenue GrowthRising profit margins alongside mid-single digit revenue growth indicate improving unit economics and market traction in its consumer health categories. That combination supports durable earnings power, funding for brand investment and margin resilience despite periodic cost pressures over the medium term.
Bears Say
Gross Margin PressureA falling gross margin signals input cost or pricing pressure that can erode core profitability if persistent. Over 2–6 months this can reduce operating leverage, constrain reinvestment capacity and require price increases or cost cuts, which may hamper demand or brand positioning.
Operational Efficiency HeadroomManagement-flagged opportunities in cost control and operations imply the company hasn’t fully optimized expenses or processes. Persistent inefficiencies can limit margin expansion and operating cash conversion, reducing the upside from sales growth and making earnings more sensitive to cost shocks.
Unsustainable FCF Growth SignalFaster FCF growth driven by a low base suggests that reported cash improvements may not persist at the same rate. If FCF growth normalizes, funding for expansion or shareholder returns could tighten, making near-term investment plans and margin improvements more dependent on operational gains.
Procter & Gamble Health Ltd. News
PGHL FAQ
What was Procter & Gamble Health Ltd.’s price range in the past 12 months?
Procter & Gamble Health Ltd. lowest stock price was ₹4725.05 and its highest was ₹6700.00 in the past 12 months.
What is Procter & Gamble Health Ltd.’s market cap?
Procter & Gamble Health Ltd.’s market cap is ₹79.19B.
When is Procter & Gamble Health Ltd.’s upcoming earnings report date?
Procter & Gamble Health Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 141 days.
How were Procter & Gamble Health Ltd.’s earnings last quarter?
Currently, no data Available
Is Procter & Gamble Health Ltd. overvalued?
According to Wall Street analysts Procter & Gamble Health Ltd.’s price is currently Undervalued.
Does Procter & Gamble Health Ltd. pay dividends?
Procter & Gamble Health Ltd. pays a Semiannually dividend of ₹45 which represents an annual dividend yield of 3.28%. See more information on Procter & Gamble Health Ltd. dividends here
What is Procter & Gamble Health Ltd.’s EPS estimate?
Procter & Gamble Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Procter & Gamble Health Ltd. have?
Procter & Gamble Health Ltd. has 16,599,382 shares outstanding.
What happened to Procter & Gamble Health Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Procter & Gamble Health Ltd.?
Currently, no hedge funds are holding shares in IN:PGHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Procter & Gamble Health Ltd.
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands. Procter & Gamble Health Limited also exports its pharmaceutical products to Sri Lanka, Nepal, Myanmar, and Maldives. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
PGHL Stock 12 Month Forecast
Average Price Target
₹6,800.00
▲(18.23% Upside)
Technical Analysis
Eveready Industries India Ltd
―
Jyothy Labs Limited
―
Surya Roshni Limited
―
Symphony Limited
―
Zydus Wellness Limited
―